Evocutis validates LabSkin model

Evocutis, the biotechnology firm, has completed R&D and validation of its full thickness skin model for use in supporting anti-ageing claims.

The company, which analyses and evaluates skincare products for the health and cosmetic markets, said the model – LabSkin – would provide the cosmetics industry with valuable data for assessing trial endpoints when testing the activity of their ingredients and products.

Because the data can be obtained prior to expensive human use studies, the model significantly reduces the risk and timelines associated with traditional product development, Evocutis claimed.

The firm plans to develop the attributes of LabSkin to reduce the risk when transitioning between simple laboratory methods and clinical studies.

Dr Richard Bojar, Evocutis chief scientific officer, said: "LabSkin provides a highly consistent substrate, which can now be used to assess anti-ageing activity and simultaneously provide additional information on irritation, penetration etc, making it a valuable tool in the development of innovative products."

Evocutis recently opened a new lab producing services dedicated to cutaneous biology, including sample processing, imaging, reporting and consultancy, at its site in Wetherby, UK.

Posted by Fiona Griffiths